Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva/Xenon’s Pain Ointment Failure Leaves Sparser Nav1.7 Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Once highly anticipated as an alternative mechanism for pain, the Nav1.7 target suffered another blow with Teva/Xenon’s failure of TV-45070 in osteoarthritis, though the class may still work in neuropathic pain.


Related Content

Genentech Seeks Partners For Biomarker-Driven Drug Development Beyond Oncology
Xenon Feels No Pain After $41M Upfront From Teva
Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit


Related Companies

Related Deals